Low sputum MMP-9/TIMP ratio is associated with airway narrowing in smokers with asthma

European Respiratory Journal

Volumn 44, Issue 4, 2014, Pages 895-904

  Chaudhuri, Rekha ^a   McSharry, Charles ^a   Brady, Jeffrey ^b   Grierson, Christal ^b   Martina Messow, C ^e   Spears, Mark ^a   Miele, Gino ^b   Nocka, Karl ^c   MacNee, William ^f   Connell, Martin ^f   Murchison, John T ^f   Sproule, Michael ^g   Hilmi, Omar J ^g   Miller, Douglas K ^d   Thomson, Neil C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Translational Medicine Research Collaboration   (United Kingdom)

^c PFIZER INC   (United States)

^d Pfizer Research Translational Medicine Research Collaboration   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; GELATINASE B; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TIMP1 PROTEIN, HUMAN; TIMP2 PROTEIN, HUMAN;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NOSE MUCOSA; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; SMOKING; SPUTUM LEVEL; ADVERSE EFFECTS; BRONCHOGRAPHY; BRONCHUS; CHEMISTRY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; SPUTUM;

ADULT; ASTHMA; BRONCHI; BRONCHOGRAPHY; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SMOKING; SPUTUM; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84907532692     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00047014     Document Type: Article

References (25)

1. Dockrell M, Partridge MR, Valovirta E. The limitations of severe asthma: the results of a European survey. Allergy 2007; 62: 134-141.
2. Chaudhuri R, McSharry C, McCoard A, et al. Role of symptoms and lung function in determining asthma control in smokers with asthma. Allergy 2008; 63: 132-135.
3. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 73: 1905-1917.
4. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716-725.
5. Thomson NC, Spears M. The role of cigarette smoking on persistent airflow obstruction in asthma. Annals Respir Med 2011; 2: 47-54.
6. Demedts IK, Brusselle GG, Bracke KR, et al. Matrix metalloproteinases in asthma and COPD. Curr Opin Pharmacol 2005; 5: 257-263.
7. Gueders MM, Foidart J-M, Noel A, et al. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 2006; 533: 133-144.
8. Vignola AM, Riccobono L, Mirabella A, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998; 158: 1945-1950.
9. Mattos W, Lim S, Russell R, et al. Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids. Chest 2002; 122: 1543-1552.
10. Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003; 28: 12-24.
11. Parameswaran K, Willems-Widyastuti A, Alagappan VK, et al. Role of extracellular matrix and its regulators in human airway smooth muscle biology. Cell Biochem Biophys 2006; 44: 139-146.
12. Chiappara G, Gagliardo R, Siena A, et al. Airway remodelling in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol 2001; 1: 85-93.
13. Vignola AM, Riccobono L, Mirabella A, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998; 158: 1945-1950.
14. Matsumoto H, Niimi A, Takemura M, et al. Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. Thorax 2005; 60: 277-281.
15. Vignola AM, Paganin F, Capieu L, et al. Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J 2004; 24: 910-917.
16. Watson AM, Benton AS, Rose MC, et al. Cigarette smoke alters tissue inhibitor of metalloproteinase 1 and matrix metalloproteinase 9 levels in the basolateral secretions of human asthmatic bronchial epithelium in vitro. J Investig Med 2010; 58: 725-729.
17. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. GINA, 2005. www. ginasthma.com.
18. Chaudhuri R, McSharry C, Brady J, et al. Sputum matrix metalloproteinase-12 in patients with chronic obstructive pulmonary disease and asthma: relationship to disease severity. J Allergy Clin Immunol 2012; 129: 655-663.
19. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
20. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med 2005; 171: 912-930.
21. Tanaka H, Miyazaki N, Oashi K, et al. Sputum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio in acute asthma. J Allergy Clin Immunol 2000; 105: 900-905.
22. Wenzel SE, Balzar S, Cundall M, et al. Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: association with asthma severity, neutrophilic inflammation, and wound repair. J Allergy Clin Immunol 2003; 111: 1345-1352.
23. Avilés B, Belda J, Margarit G, et al. Marcadores de remodelado bronquial en el esputo inducido de fumadores sanos [Markers of airway remodeling in induced sputum from healthy smokers]. Arch Bronconeumol 2006; 42: 235-240.
24. Hoshino M, Takahashi M, Takai Y, et al. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol 1999; 104: 356-363.
25. Cataldo D, Bettiol J, Noël A, et al. Matrix metalloproteinase-9, but not tissue inhibitor of matrix metalloproteinase-1, increases in the sputum from allergic asthmatic patients after allergen challenge. Chest 2002; 122: 1553-1559.